Patent ID: 11925664
Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of genomically modifying a population of human immune cells, the method comprising contacting ex vivo or in vitro the population of human immune cells with:
a) a polynucleic acid that encodes an exogenous T cell receptor or a chimeric antigen receptor, wherein said exogenous T cell receptor or said chimeric antigen receptor binds a cancer antigen;
b) a ribonuclear protein complex, wherein the ribonuclear protein complex comprises:
i) a guide RNA that binds a first gene locus within said human immune cells; and
ii) a Cas protein; and
c) a polynucleic acid that encodes a homologous recombination enhancer,
wherein the population of human immune cells are synchronized prior to said contacting with the ribonuclear protein complex, wherein the ribonuclear protein complex performs a genomic disruption within a target sequence of the first gene locus that comprises any one of SEQ ID NOS: 75-86, thereby generating genomically modified human immune cells, wherein the genomic disruption reduces or eliminates production of a protein encoded by the first gene locus as compared to a comparable human immune cell lacking the genomic disruption in the first gene locus, wherein the homologous recombination enhancer suppresses non-homologous end joining, and wherein said genomically modified human immune cells express said exogenous T cell receptor or chimeric antigen receptor.